ADAM23|αvβ3在大肠癌中的表达与大肠癌肝转移的关系

目的：探讨ADAM23，αvβ3在大肠癌中的表达及其与肝转移等临床病理因素的关系。方法：应用免疫组化和RT-PCR方法检测53例大肠癌及其癌旁组织及20例良性病变组织中ADAM23，αvβ3的表达情况，并分析两者的蛋白表达与临床病理因素的关系。结果：大肠癌组织中ADAM23蛋白与mRNA阳性表达率明显低于癌旁组织与良性病变组织（均P<0.05），而αvβ3蛋白与mRNA阳性表达率明显高于癌旁组织与良性病变组织（均P<0.05）。大肠癌组织中ADAM23和αvβ3蛋白的表达呈负相关（χ2=10.3390；r=-0.637，P<0.01）。ADAM23和αvβ3的蛋白表达与患者的性别，年龄及分化程度无关（均P>0.05），而与临床分期，淋巴转移及肝转移有关，此外ADAM23蛋白的表达还与大肠癌浸润深度有关（均P<0.05）。结论：大肠癌中ADAM23呈低表达，αvβ3呈高表达，两者可能与大肠癌的肝转移等不良临床转归有关。

AdAM23 and αvβ3 expression in colorectal cancer and their relations with liver metastases

Objective: To investigate the ADAM23 and αvβ3 expressions in colorectal cancer and their relations with liver metastases and other clinicopathologic features. Methods: The protein and mRNA expressions of ADAM23 and αvβ3 in 53 specimens of colorectal cancer and their adjacent tissue, and 20 specimens of benign disease colorectal tissue were detected by immunohistochemical staining and RT-PCR method. The relations of their protein expressions with the clinicopathologic features were analyzed. Results: The positive expression rates of both ADAM23 protein and mRNA were significantly lower in colorectal cancer tissues than those in adjacent tissues and benign disease colorectal tissues (all P<0.05), whereas the positive expression rates of both αvβ3 protein and mRNA were significantly higher in colorectal cancer tissues than those in adjacent tissues and benign disease colorectal tissues (all P<0.05). There was a negative correlation between the protein expressions of ADAM23 and αvβ3 in colorectal cancer (χ2=10.3390; r=–0.637, P<0.01). The protein expressions of ADAM23 and αvβ3 were not related with age, sex, or degree of differentiation, but significantly associated with clinical stage, lymph node metastasis and liver metastasis (all P<0.05). In addition, ADAM23 protein expression was also relevant to depth of tumor infiltration (P<0.05). Conclusion: ADAM23 expression is decreased while αvβ3 expression is increased in colorectal cancer, and both are associated with colorectal cancer liver metastases and other unfavorable clinical outcomes.